Cargando…

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Patients with lung cancer benefit from more effective treatments, such as targeted therapies, and the overall survival has increased in the past decade. However, the efficacy of targeted therapies is limited due to the emergence of resistance. Growing evidence suggests that resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delahaye, Celia, Figarol, Sarah, Pradines, Anne, Favre, Gilles, Mazieres, Julien, Calvayrac, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179469/ https://www.ncbi.nlm.nih.gov/pubmed/35681591 http://dx.doi.org/10.3390/cancers14112613

Ejemplares similares

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
por: Calvayrac, Olivier, et al.
Publicado: (2016)

Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages
por: Guibert, Nicolas, et al.
Publicado: (2020)

Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!
por: Durin, Lucile, et al.
Publicado: (2020)

Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer
por: Laplagne, Chloé, et al.
Publicado: (2020)

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
por: Guibert, Nicolas, et al.
Publicado: (2017)

Epigenetic regulation of RhoB loss of expression in lung cancer
por: Mazières, Julien, et al.
Publicado: (2007)

Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges
por: Ulrich, Bryan, et al.
Publicado: (2021)

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
por: Mhanna, Laurent, et al.
Publicado: (2019)

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
por: Delmas, Audrey, et al.
Publicado: (2015)

Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?
por: Khalifa, Jonathan, et al.
Publicado: (2021)

Phenotypic and Histological Distribution Analysis Identify Mast Cell Heterogeneity in Non-Small Cell Lung Cancer
por: Leveque, Edouard, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer—an IMMUNOTARGET case series
por: Mushtaq, Rao, et al.
Publicado: (2022)

Reversible inactivation of the transcriptional function of P53 protein by farnesylation
por: Couderc, Bettina, et al.
Publicado: (2006)

Alternative Processing of the U2 Small Nuclear RNA Produces a 19–22nt Fragment with Relevance for the Detection of Non-Small Cell Lung Cancer in Human Serum
por: Mazières, Julien, et al.
Publicado: (2013)

Targeted therapy for localized non-small-cell lung cancer: a review
por: Paleiron, Nicolas, et al.
Publicado: (2016)

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
por: Reita, Damien, et al.
Publicado: (2022)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer
por: Pasquier, Corentin, et al.
Publicado: (2023)

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion
por: Berghoff, Anna S., et al.
Publicado: (2019)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

Integration of interventional bronchoscopy in the management of lung cancer
por: Guibert, Nicolas, et al.
Publicado: (2015)

Three-Dimensional in vitro Models of Healthy and Tumor Brain Microvasculature for Drug and Toxicity Screening
por: Piantino, Marie, et al.
Publicado: (2021)

Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
por: Liu, Shuliang, et al.
Publicado: (2016)

Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
por: Wang, Zixi, et al.
Publicado: (2022)

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
por: Wu, Jiajia, et al.
Publicado: (2022)

Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer
por: Crintea, Andreea, et al.
Publicado: (2023)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)

The RND1 Small GTPase: Main Functions and Emerging Role in Oncogenesis
por: Mouly, Laetitia, et al.
Publicado: (2019)

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
por: Liu, Zhe, et al.
Publicado: (2021)

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
por: Chhouri, Houssein, et al.
Publicado: (2023)

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung
por: Saffroy, Raphaël, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
por: Karlsen, Emma-Anne, et al.
Publicado: (2021)

Deciphering Prunus Responses to PPV Infection: A Way toward the Use of Metabolomics Approach for the Diagnostic of Sharka Disease
por: Espinoza, Christian, et al.
Publicado: (2021)

Biological Effects and Applications of Bulk and Surface Acoustic Waves on In Vitro Cultured Mammal Cells: New Insights
por: Figarol, Agathe, et al.
Publicado: (2022)

Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging
por: Chen, Xiao, et al.
Publicado: (2017)

Protocol to select conformation-specific intracellular antibodies for targeted protein degradation in an engineered cell line
por: Bery, Nicolas, et al.
Publicado: (2020)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n3ovl62t4vu580e1d8vol4k313